Association Between Body Mass Index and Cardiac Dysfunction During Human Epidermal Growth Factor Receptor 2 Inhibitor Therapy for Breast Cancer
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background: The administration of human epidermal growth factor receptor 2 inhibitors (HER2i) has improved the survival of patients with breast cancer; however, cancer therapy-related cardiac dysfunction (CTRCD) has been reported as an adverse effect. In this study we evaluated the incidence of CTRCD associated with HER2i treatment and explored risk factors for a decrease in left ventricular function. Methods and Results: ) was used to divide patients into low- and high-BMI groups. Changes in red cell distribution width (RDW), left ventricular ejection fraction (LVEF), and global longitudinal strain (GLS) were evaluated. A total of 32 patients showed a decrease in LVEF 6 months after treatment initiation, and 2 had LVEF <50% with a ≥10% decrease. The rate of LVEF decrease was significantly greater in the low-BMI group than in the high-BMI group (-5.1% vs. -0.4%, P=0.023). No association was observed between RDW or GLS and LVEF. Conclusions: Low BMI was associated with a greater risk of cardiotoxicity during HER2i treatment. Careful cardiac monitoring is particularly recommended for patients with low BMI.
Source: Circulation Reports
Institution: Kanazawa Medical University
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7170154706
FWCI:
Cites:
Cited by:
Related to: